Status:

COMPLETED

Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / Docetaxel

Lead Sponsor:

Krankenhaus Nordwest

Conditions:

Non Small Cell Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The study compares two combinations of chemotherapy in patients with advanced or metastatic NSCLC: 50% of the patients are treated with cisplatin and docetaxel, the other 50% with oxaliplatin and doce...

Detailed Description

Cispaltin based chemotherapies are standard for palliative first-line therapy in patients with advanced or metastatic NSCLC. Due to contraindications to cisplatin, this substance can not be used in a ...

Eligibility Criteria

Inclusion

  • histologically or cytologically confirmed NSCLC stage IIIB or IV.
  • no previous chemotherapy in metastatic state
  • male and female patients aged \> 18 years
  • ECOG ≤ 2
  • Leukocytes \> 3.000/µl
  • Thrombocytes \> 100.000/µl
  • Serum creatinine ≤ 1.25x normal value, or Creatinine Clearance \> 45 ml/min
  • previous radiation \< 25% bone marrow region allowed. Previous radiation of whole pelvis not allowed
  • parallel radiation allowed, if target lesion outside of radiation field
  • written informed consent
  • life expectancy \> 3 months

Exclusion

  • hypersensibility against Cisplatin, Oxaliplatin or Docetaxel
  • Neoadjuvant or adjuvant chemotherapy within the last 6 months
  • radiation within the last 28 days
  • severe systemic comorbidities
  • Cardiomyopathy or cardiac insufficiency stage II-IV according to NYHA
  • malignant secondary disease, dated back \< 5 years (exception: In-situ-carcinoma of the cervix uteri, adequately treated skin basal cell carcinoma)
  • brain metastases
  • severe non-surgical comorbidities or acute infection
  • peripheral polyneuropathy \> NCI grade II
  • severe liver dysfunction AST/ALT\>3,5xULN, AP\>6xULN, Bilirubin\>1,5xULN)
  • participation in parallel trial
  • pregnancy and lactation
  • reduced hearing

Key Trial Info

Start Date :

August 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2011

Estimated Enrollment :

88 Patients enrolled

Trial Details

Trial ID

NCT01222312

Start Date

August 1 2008

End Date

November 1 2011

Last Update

November 29 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Krankenhaus Nordwest

Frankfurt am Main, Germany, 60488